CBD liver study to inform FDA regulation gains support for deployment next month

FDA-CBD.jpg

A third-party consumer research study looking at CBD’s effects on humans, meant to help gather liver safety data that the U.S. Food and Drug Administration needs to move forward with regulation, is set to begin in July.

The protocol for the study, sponsored and led by ValidCare, a Colorado-based firm that conducts clinical and market intelligence research for the hemp and healthcare industries, was developed with significant feedback from the FDA’s working group focused on CBD.

Click Here to read the rest of the article

Now is the time to be a leader in the CBD industry. Get Certified!

Joe Medrano, ARM, CCBDCComment